低分子肝素对复发性自然流产活产率的比较效果:系统评价与网状Meta分析
该系统评价与网状Meta分析纳入22项随机对照试验共4773名复发性自然流产女性,比较五种低分子肝素与对照组的活产率及不良妊娠结局。依诺肝素显著提高活产率(RR 1.19,95%CI 1.06-1.36),并降低子痫前期、早产和妊娠丢失风险;20mg与40mg依诺肝素均改善活产率,20mg更有效。
要点
- 依诺肝素较对照组显著提高活产率(RR 1.19,95%CI 1.06-1.36),证据置信度为中等。
- 依诺肝素降低子痫前期(RR 0.53)、早产(RR 0.59)和妊娠丢失(RR 0.55)风险。
- 依诺肝素20mg(RR 1.53)与40mg(RR 1.18)均改善活产率,20mg剂量更有效。
核心结论
- 依诺肝素较对照组是提高活产率最有效的低分子肝素,并显著降低子痫前期、早产和妊娠丢失风险。
- 基于剂量的亚组分析显示依诺肝素20mg与40mg均改善活产率,20mg剂量效果更佳。
研究设计与样本
- 系统评价与网状Meta分析,纳入22项随机对照试验共4773名复发性自然流产女性,涉及五种低分子肝素,所有比较均针对对照组。
- 检索PubMed、Web of Science、Cochrane Library和Embase自建库至2024年7月1日的文献。
- 纳入标准为随机对照试验,受试者为接受低分子肝素的复发性自然流产女性,随访至少12周。
- 治疗为低分子肝素单药或非随机背景抗凝治疗上加用低分子肝素,对照组为安慰剂或其他抗凝治疗。
- 排除交叉设计试验或涉及已撤市药物的试验。
主要发现
- 依诺肝素提高活产率(RR 1.19,95%CI 1.06-1.36),累积排序曲线下面积73%,证据置信度为中等。
- 依诺肝素降低子痫前期风险(RR 0.53,95%CI 0.28-0.92),累积排序曲线下面积85%。
- 依诺肝素降低早产风险(RR 0.59,95%CI 0.41-0.86),累积排序曲线下面积85%。
- 依诺肝素降低妊娠丢失风险(RR 0.55,95%CI 0.38-0.76),累积排序曲线下面积82%。
- 依诺肝素20mg提高活产率(RR 1.53,95%CI 1.08-2.25),累积排序曲线下面积89%;40mg提高活产率(RR 1.18,95%CI 1.04-1.38),累积排序曲线下面积59%;两种剂量均显著降低妊娠丢失风险。
关键数值与推荐
- 采用Risk of Bias 2.0工具评估偏倚,采用Confidence in Network Meta-Analysis框架评价证据质量。
- 网状Meta分析采用贝叶斯框架整合直接与间接证据,计算风险比及95%置信区间,马尔可夫链蒙特卡洛方法生成后验分布以比较和排序治疗。
- 进行亚组、回归和敏感性分析评估各种因素对结果的影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the effectiveness and safety of low molecular weight heparins (LMWHs) on live birth rates and adverse pregnancy outcomes in individuals experiencing recurrent spontaneous abortion (RSA). DATA SOURCES: PubMed, Web of Science, the Cochrane Library, and Embase from database inception to July 1, 2024. STUDY ELIGIBILITY CRITERIA: Eligible randomized controlled trials enrolled women with RSA who received LMWH, with a follow-up duration of at least 12 weeks. The treatment was either monotherapy with LMWH or added LMWH to nonrandomized background anticoagulant treatments, with the control group being placebo and other anticoagulant treatments. Trials with a crossover design or involving withdrawn drugs were also excluded. STUDY APPRAISAL AND SYNTHESIS METHODS: We assessed bias using the Risk of Bias 2.0 tool and evaluated evidence quality with the Confidence in Network Meta-Analysis framework. The network meta-analysis employed a Bayesian framework to integrate direct and indirect evidence, calculating risk ratios and 95% confidence intervals. Markov chain Monte Carlo methods generated posterior distributions, allowing comparison and ranking of treatments. Subgroup, regression, and sensitivity analyses assessed the impact of various factors on the results. RESULTS: This network meta-analysis included 22 trials involving 4773 participants across five different LMWH drugs, with all comparisons made against the control group. Among the five drugs, enoxaparin showed significant benefits. It notably improved live birth rates (LBR) (Risk Ratios 1.19, (95% confidence intervals 1.06 to 1.36), surface under the cumulative ranking curve 73%; moderate confidence of evidence), reduced the risk of pre-eclampsia (0.53, (0.28-0.92), 85%), lowered preterm delivery (0.59, [0.41-0.86], 85%), and decreased pregnancy loss (0.55, [0.38-0.76], 82%). Further analysis of 7 different LMWH doses revealed that both enoxaparin 20mg (1.53, [1.08-2.25], 89%) and 40mg (1.18, [1.04-1.38], 59%) significantly improved LBR, with the 20mg dose proving more effective. Both doses also significantly reduced the risk of pregnancy loss. CONCLUSION: Enoxaparin proved to be the most effective LMWH in increasing LBR compared to the control group. It also significantly lowered the risks of pre-eclampsia, preterm delivery, and pregnancy loss. A dosage-based subgroup analysis showed that both 20mg and 40mg of enoxaparin improved LBR, with the 20mg dose demonstrating greater effectiveness. El resumen está disponible en Español al final del artículo.
引用
- Huang W, Yu Y, Chen L, et al. Comparative effectiveness of low molecular weight heparin on live birth for recurrent spontaneous abortion: systematic review and network meta-analysis. Am J Obstet Gynecol MFM. 2024. PMID: 39603530. doi:10.1016/j.ajogmf.2024.101572
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。